Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus.

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: liraglutide

First Posted Date: 2015-07-22

Last Posted Date: 2018-09-05

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 635

Registration Number: NCT02505334

Locations: 🇯🇵
Novo Nordisk Investigational Site, Yokohama-shi, Japan

A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes

Interventions: Drug: insulin degludec/liraglutide
Drug: insulin glargine

First Posted Date: 2015-07-17

Last Posted Date: 2019-11-27

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1012

Registration Number: NCT02501161

Locations: 🇬🇧
Novo Nordisk Investigational Site, Wolverhampton, United Kingdom

Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: insulin aspart
Drug: Faster-acting insulin aspart
Drug: insulin degludec

First Posted Date: 2015-07-16

Last Posted Date: 2019-06-12

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1108

Registration Number: NCT02500706

Locations: 🇨🇳
Novo Nordisk Investigational Site, Taoyuan, Taiwan

Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects

Phase 1

Completed

Conditions: Congenital Bleeding Disorder
Haemophilia A

Interventions: Drug: placebo
Drug: Concizumab

First Posted Date: 2015-07-07

Last Posted Date: 2017-07-21

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 24

Registration Number: NCT02490787

Locations: 🇬🇧
Novo Nordisk Investigational Site, Southampton, United Kingdom

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Insulin 320 in Healthy Subjects

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes
Healthy

Interventions: Drug: Insulin 320
Drug: insulin glargine
Drug: placebo

First Posted Date: 2015-06-23

Last Posted Date: 2016-08-01

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 84

Registration Number: NCT02479022

Trial to Compare NNC0123-0000-0338 in a Tablet Formulation and Insulin Glargine in Subjects With Type 2 Diabetes Currently Treated With Oral Antidiabetic Therapy

Phase 2

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: insulin 338 (GIPET I)
Drug: insulin glargine
Drug: placebo

First Posted Date: 2015-06-12

Last Posted Date: 2019-03-18

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 50

Registration Number: NCT02470039

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes

Phase 2

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: placebo
Drug: liraglutide
Drug: semaglutide

First Posted Date: 2015-06-03

Last Posted Date: 2019-07-31

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 706

Registration Number: NCT02461589

Locations: 🇬🇧
Novo Nordisk Investigational Site, Truro, United Kingdom

Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus

Phase 2

Completed

Conditions: Metabolism and Nutrition Disorder
Obesity

Interventions: Drug: semaglutide
Drug: liraglutide
Drug: placebo

First Posted Date: 2015-05-25

Last Posted Date: 2020-04-17

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 957

Registration Number: NCT02453711

Locations: 🇬🇧
Novo Nordisk Investigational Site, Rotherham, United Kingdom

A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients

Phase 4

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: biphasic insulin aspart 30
Drug: insulin glargine
Drug: insulin aspart

First Posted Date: 2015-05-25

Last Posted Date: 2019-02-08

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 335

Registration Number: NCT02453685

Locations: 🇦🇪
Novo Nordisk Investigational Site, Umm Al Quwain, United Arab Emirates

A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function

Phase 2

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: NNC0114-0006
Drug: placebo
Drug: liraglutide

First Posted Date: 2015-05-13

Last Posted Date: 2021-04-09

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 308

Registration Number: NCT02443155

Locations: 🇬🇧
Novo Nordisk Investigational Site, Swansea, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy